To investigate the effectiveness of compounded creams in the treatment of chronic pain conditions, study authors performed a double-blind, randomized, parallel study comparing creams compounded with an active ingredient to placebo creams.
Over 1400 clinical trials and research studies were reviewed by a panel of 13 experts to develop the new guideline.
Using data from the 2011 to 2016 National Vital Statistics System-Mortality files, the authors conducted a literal text analysis of death certificates to identify drugs mentioned as contributing to the cause of overdose death.
To investigate the association between hormone therapy and carpal tunnel syndrome risk, researchers conducted a secondary analysis of the Women’s Health Initiative (WHI) hormone therapy trials.
The approval was based on data from 2 vehicle-controlled Phase 3 trials.
While approved in Europe, Asia and Latin America, tianeptine is an unscheduled pharmaceutical agent in the US that has been linked to serious adverse events, including death, when used for recreational purposes.
Reports of pump failure, dosing errors, as well as other possible safety issues have prompted the Agency to issue the alert to make prescribers aware of the dangers associated with using medications not approved for intrathecal use.
Recommendations on the use of these agents in this patient population were published in a Views and Perspectives paper in the journal Headache.
The recommendations have been published in the AGA’s official journal, Gastroenterology.
In this prospective, cohort study, patients (N=18) were randomized to receive gabapentin 400-800mg 3 times daily then pregabalin 150-300mg twice daily or vice versa; each treatment regimen was taken for 8 weeks with a 1-week washout period in between.
